Joly P, Vasseur E, Esteve E, Leibowitch M, Tilly H, Vaillant L, Wechsler J, Thomine E, De Muret A, Dreyfus F
Services de Dermatologie, Anatomo-Pathologie, Hématologie, CHU, Rouen, France.
Br J Dermatol. 1995 Apr;132(4):506-12. doi: 10.1111/j.1365-2133.1995.tb08703.x.
Primary cutaneous medium and large cell lymphomas (MLCL) other than mycosis fungoides (MF) are rare, and their prognosis and treatment are controversial. The clinical, immunohistological and follow-up data of 54 well-documented cases of primary cutaneous MLCL other than MF, seen in our institutions over a 14-year period, were retrospectively reviewed, in order to determine the prognostic factors related to these lymphomas, and to analyse the results obtained with different treatment regimens. Forty-six patients presented with a solitary tumour or with localized lesions, and eight had disseminated cutaneous lesions. According to the updated Kiel classification, 45 cases (83%) corresponded to B-cell lymphomas: centroblastic lymphomas, 32 cases; centroblastic-centrocytic lymphomas, 11 cases; immunoblastic lymphomas, two cases. Nine cases (17%) were classified as T-cell lymphomas: pleomorphic medium and large cell lymphomas, eight cases; anaplastic large cell lymphoma, one case. Four of eight patients with disseminated skin lesions had a T-cell lymphoma, whereas 41 of 46 patients with a solitary tumour had a B-cell lymphoma. Patients with disseminated skin lesions and elevated serum lactate dehydrogenase (LDH) levels had a poor prognosis. Comparison of patients' overall survival, depending on immunohistological subtype, showed that the median survival of patients with pleomorphic T-cell lymphoma was 2.5 years, whereas it was not reached at 12 years for patients with centroblastic-centrocytic and centroblastic lymphoma. The eight patients with disseminated skin lesions were treated with polychemotherapy.(ABSTRACT TRUNCATED AT 250 WORDS)
除蕈样肉芽肿(MF)外的原发性皮肤中、大细胞淋巴瘤(MLCL)较为罕见,其预后和治疗存在争议。回顾性分析了我们机构在14年期间诊治的54例有完整记录的非MF原发性皮肤MLCL的临床、免疫组织学及随访数据,以确定与这些淋巴瘤相关的预后因素,并分析不同治疗方案的疗效。46例患者表现为孤立性肿瘤或局限性病变,8例有皮肤播散性病变。根据更新的 Kiel 分类,45例(83%)为B细胞淋巴瘤:中心母细胞性淋巴瘤32例;中心母细胞-中心细胞性淋巴瘤11例;免疫母细胞性淋巴瘤2例。9例(17%)为T细胞淋巴瘤:多形性中、大细胞淋巴瘤8例;间变性大细胞淋巴瘤1例。8例皮肤播散性病变患者中有4例为T细胞淋巴瘤,而46例孤立性肿瘤患者中有41例为B细胞淋巴瘤。皮肤播散性病变且血清乳酸脱氢酶(LDH)水平升高的患者预后较差。根据免疫组织学亚型比较患者的总生存率,结果显示多形性T细胞淋巴瘤患者的中位生存期为2.5年,而中心母细胞-中心细胞性淋巴瘤和中心母细胞性淋巴瘤患者在12年时仍未达到中位生存期。8例皮肤播散性病变患者接受了多药化疗。(摘要截短至250字)